仙琚製藥(002332.SZ):放棄參股公司索元生物股權優先受讓權和增資優先認購權
格隆匯 7 月 9日丨仙琚製藥(002332.SZ)公佈,索元生物醫藥(杭州)有限公司(“索元生物”)系公司的參股公司,公司持有其11.1935%的股權。
公司於2020年7月初收到索元生物關於股東股權轉讓和員工持股平台增資的通知,索元生物股東廣州越秀新興產業創業投資合夥企業(有限合夥)(“越秀新興產投”)擬以6606.7236萬元人民幣的轉讓價格,將其所持有的索元生物註冊資本241.39萬元人民幣(對應2.7293%股權)轉讓給北京四合元醫醫藥科技中心(有限合夥);索元生物股東青島金石灝汭投資有限公司(“青島金石”)擬以3000萬元人民幣的轉讓價格,將所持有的公司註冊資本825萬元人民幣(對應9.3279%股權)轉讓給中信證券投資有限公司(青島金石與中信證券投資有限公司是屬於同一控制人中信證券股份有限公司控制的關聯企業)。針對以上股東的股權轉讓,公司結合實際經營發展定位,擬放棄上述股權轉讓的優先受讓權。
在此次股權轉讓後,索元生物擬向其中高層核心骨幹人員設立的員工持股平台增資1116.7169萬元人民幣註冊資本,索元生物註冊資本將由目前的8844.4252萬元人民幣增加到9961.1421萬元人民幣。此次增資由廈門勵元投資諮詢合夥企業(有限合夥)、廈門迪元投資諮詢合夥企業(有限合夥)、Alphanovo LP和Betanovo LP四家企業參與(以上四家合夥企業均為由索元生物中高層核心骨幹人員設立的員工持股平台)。參與增資的四家企業擬以現金出資合計1116.7169萬元人民幣認購索元生物的新增註冊資本,公司及索元生物的其他股東均放棄此次增資優先認購權。
此次增資完成後,公司持有索元生物的股權比例由原來的11.1935%降至9.9386%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.